Skip to content

Study · Observational study · n = 41 · 2012

4 results

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP

Alimentary pharmacology & therapeutics24 Nov 2011Cited by 72 (Europe PMC)

PMID22111942 (opens in a new tab)DOI10.1111/j.1365-2036.2011.04923.x (opens in a new tab)PepBankPUB-22111942
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In PLD patients, lanreotide was linked to a 4% liver volume decrease after 12 months (IQR -8% to -1%).

    In plain wordsIn PLD patients, lanreotide was linked to a 4% decrease in liver volume after 12 months.

    Peptide
    Lanreotide
    Outcome
    DecreaseLiver volume after 12 months
    Study

    n = 41

    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg/month · 12 monthsAs given in this study (human).

    Measurements

    Relative change in liver volume
    −4%
    after 12 months of treatment
    IQR of relative change in liver volume
    −8 to −1%
    after 12 months of treatment

    Source sentences

    Summary
    Liver volume decreased by 4% (IQR -8% to -1%) after 12 months of treatment.
    2 context sentences
    Summary · context
    This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD.
    Summary · context
    The length of total treatment was 12 months.
  2. 02HumanObservational studyEfficacy outcome

    In PLD patients, lanreotide was linked to a 4% liver volume decrease during the first 6 months (IQR -6% to -1%).

    In plain wordsIn PLD patients, lanreotide was linked to a 4% liver volume decrease during the first 6 months.

    Peptide
    Lanreotide
    Outcome
    DecreaseLiver volume during first six months
    Study

    n = 41

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg/month · 6 monthsAs given in this study (human).

    Measurements

    Relative change in liver volume
    −4%
    first 6 months of treatment
    IQR of relative change in liver volume
    −6 to −1%
    first 6 months of treatment

    Source sentences

    Summary
    The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR -6% to -1%)).
    2 context sentences
    Summary · context
    This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD.
    Summary · context
    The length of total treatment was 12 months.
  3. 03HumanObservational studyEfficacy outcome

    In PLD patients receiving lanreotide, liver volume remained unchanged during the following 6 months.

    In plain wordsIn PLD patients receiving lanreotide, liver volume remained unchanged during the following 6 months.

    Peptide
    Lanreotide
    Outcome
    No significant changeLiver volume during following six months
    Study

    n = 41

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg/month · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Liver volume remained unchanged during the following 6 months.
    2 context sentences
    Summary · context
    This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD.
    Summary · context
    The length of total treatment was 12 months.
  4. 04HumanObservational studyEfficacy outcome

    In PLD patients, stopping lanreotide was linked to a 4% liver volume increase 6 months later (IQR 0-6%).

    In plain wordsIn PLD patients, stopping lanreotide was linked to a 4% liver volume increase 6 months later.

    Peptide
    Lanreotide
    Outcome
    IncreaseLiver volume after stopping treatment
    Study

    n = 22

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg/month · 12 monthsAs given in this study (human).

    Measurements

    Relative change in liver volume
    4%
    6 months after end of treatment, n = 22
    IQR of relative change in liver volume
    0 to 6%
    6 months after end of treatment, n = 22

    Source sentences

    Summary
    We found that liver volume increased by 4% (IQR 0-6%) 6 months after end of treatment (n = 22).
    2 context sentences
    Summary · context
    This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD.
    Summary · context
    The length of total treatment was 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.